CIK 0001750284
- Non-accelerated filer
- Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 300409740
- Phone
- +1 415-651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-11-19 | BVF PARTNERS L P/IL Director | Conversion · Series C Convertible Preferred Stock | −760,155 | 0 | ||
| 2020-11-19 | BVF PARTNERS L P/IL Director | Conversion · Series C Convertible Preferred Stock | −522,403 | 0 | ||
| 2020-11-19 | BVF PARTNERS L P/IL Director | Conversion · Series C Convertible Preferred Stock | −73,399 | 0 | ||
| 2020-11-18 | Harmon Cyrus Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +1,076 | 1,076 | ||
| 2020-11-18 | BVF PARTNERS L P/IL Director | Grant or award · Stock Option (Right to buy) | +21,520 | 21,520 | ||
| 2020-11-18 | BVF PARTNERS L P/IL Director | Grant or award · Stock Option (Right to buy) | +21,520 | 21,520 | ||
| 2020-11-18 | BVF PARTNERS L P/IL Director | Grant or award · Stock Option (Right to buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Graham G. Walmsley Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Graham G. Walmsley Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Graham G. Walmsley Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | RAPPAPORT ANDREW Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Myles David C. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +179,340 | 179,340 | ||
| 2020-11-18 | Moriarty John B EVP, Ch. Legal Officer & Sec. | Grant or award · Stock Option (Right to Buy) | +161,406 | 161,406 | ||
| 2020-11-18 | MCCORMICK FRANK Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Kushner Peter J. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +179,340 | 179,340 | ||
| 2020-11-18 | Kovacs Shane William Charles Ch. Operating & Financial Off. | Grant or award · Stock Option (Right to Buy) | +107,604 | 107,604 | ||
| 2020-11-18 | Hrustanovic Gorjan Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Hrustanovic Gorjan Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Hrustanovic Gorjan Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2020-11-18 | Horning Sandra Director | Grant or award · Stock Option (Right to Buy) | +86,083 | 86,083 |
Page 22 of 24 · 465 trades